Provides that purchase of insulin is not subject to deductible; requires health insurers to limit copayments and coinsurance for insulin; requires insulin manufacturers to submit report to Commissioner of Banking and Insurance.
Eliminates insulin deductibles, caps copayments, and mandates manufacturer pricing disclosures to reduce patient medication costs in New Jersey.